GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Other Current Receivables

Roquefort Therapeutics (LSE:ROQ) Other Current Receivables : £0.03 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Other Current Receivables?

Roquefort Therapeutics's Other Current Receivables for the quarter that ended in Dec. 2024 was £0.03 Mil.

Roquefort Therapeutics's quarterly Other Current Receivables declined from Dec. 2023 (£0.16 Mil) to Jun. 2024 (£0.00 Mil) but then increased from Jun. 2024 (£0.00 Mil) to Dec. 2024 (£0.03 Mil).

Roquefort Therapeutics's annual Other Current Receivables increased from Dec. 2022 (£0.10 Mil) to Dec. 2023 (£0.16 Mil) but then declined from Dec. 2023 (£0.16 Mil) to Dec. 2024 (£0.03 Mil).


Roquefort Therapeutics Other Current Receivables Historical Data

The historical data trend for Roquefort Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Other Current Receivables Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Other Current Receivables
2.16 0.10 0.16 0.03

Roquefort Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Current Receivables Get a 7-Day Free Trial 0.10 0.24 0.16 - 0.03

Roquefort Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Roquefort Therapeutics Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines